IP Library Granted Patent US 10,058,596
Granted Patent B2
US 10,058,596 · App. 13/719,176 · Granted Aug 28, 2018

Composition for enzymatic debridement

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,058,596
App. No.
13/719,176
Granted
Aug 28, 2018
Kind
B2
Abstract

Methods and compositions for the enzymatic debridement of wounds are provided. Methods for preparing enzymatic debridement compositions are also provided. In one embodiment, an enzymatic debridement composition prepared by dissolving crude bromelain in a composition comprising a weak acid, and filtering and/or dialyzing the dissolved crude bromelain to obtain the enzymatic debridement composition is provided.

Claims (40)

1. A method of preparing an enzymatic debridement composition wherein the method consists of:

(a) dissolving crude bromelain in a composition comprising a weak acid;

(b) filtering and/or dialyzing the dissolved crude bromelain to obtain the enzymatic debridement composition; and

(c) optionally lyophilizing the enzymatic debridement composition.

2. The method of claim 1 , wherein the method consists of:

(a) dissolving crude bromelain in a composition comprising a weak acid;

(b) filtering the dissolved crude bromelain to obtain a filtered bromelain composition;

(c) dialyzing the filtered bromelain composition to obtain the enzymatic debridement composition; and

(d) optionally lyophilizing the enzymatic debridement composition.

3. The method of claim 1 , wherein the weak acid is selected from the group consisting of acetic acid, trichloroacetic acid, oxalic acid, formic acid, benzoic acid, and citric acid.

4. The method of claim 1 , wherein the enzymatic debridement composition is in the form of liquid or powder.

5. A method of preparing an enzymatic debridement composition wherein the method consists of:

(a) dissolving crude bromelain in a composition comprising a weak acid;

(b) filtering and/or dialyzing the dissolved crude bromelain to obtain the enzymatic debridement composition;

(c) optionally lyophilizing the enzymatic debridement composition to obtain a lyophilized enzymatic debridement composition; and

(d) formulating the lyophilized enzymatic debridement composition into a liquid, a powder, a film, a gel, a foam, or a spray.

6. The method of claim 5 , wherein the gel comprises 10% by weight of the lyophilized enzymatic debridement composition.

7. The method of claim 3 , wherein the crude bromelain is dissolved in a composition comprising 0.3M acetic acid.

8. The method of claim 1 , wherein the dissolved crude bromelain is filtered through a 0.2μm pore filter.

9. The method of claim 1 , wherein the filtered bromelain is dialyzed through a 12,400 molecular weight cut-off membrane.

10. A method of preparing an enzymatic debridement composition wherein the method consists of:

(a) dissolving crude bromelain in a composition comprising a weak acid;

(b) filtering and/or dialyzing the dissolved crude bromelain to obtain the enzymatic debridement composition;

(c) optionally lyophilizing the enzymatic debridement composition to obtain a lyophilized enzymatic debridement composition; and

(d) applying the enzymatic debridement composition or the lyophilized enzymatic debridement composition on a wound dressing.

11. A method for debridement of devitalized tissue from a subject consisting of:

(a) dissolving crude bromelain in a composition comprising a weak acid;

(b) filtering and/or dialyzing the dissolved crude bromelain to obtain the enzymatic debridement composition;

(c) optionally lyophilizing the enzymatic debridement composition to obtain a lyophilized enzymatic debridement composition;

(d) contacting the devitalized tissue with the enzymatic debridement composition or the lyophilized enzymatic debridement composition to dissolve the devitalized tissue; and

(e) removing the dissolved devitalized tissue.

12. The method of claim 11 , wherein the method consists of:

(a) dissolving crude bromelain in a composition comprising a weak acid;

(b) filtering the dissolved crude bromelain to obtain a filtered bromelain composition;

(c) dialyzing the filtered bromelain composition to obtain the enzymatic debridement composition;

(d) optionally lyophilizing the enzymatic debridement composition to obtain a lyophilized enzymatic debridement composition;

(e) contacting the devitalized tissue with the enzymatic debridement composition or the lyophilized enzymatic debridement composition to dissolve the devitalized tissue; and

(f) removing the dissolved devitalized tissue.

13. The method of claim 11 , wherein the enzymatic debridement composition is in contact with the devitalized tissue for 1 to 48 hours before the dissolved devitalized tissue is removed.

14. The method of claim 11 , wherein contacting the devitalized tissue is by coating the devitalized tissue with the enzymatic debridement composition or by injecting the enzymatic debridement composition into the devitalized tissue.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: 3M INNOVATIVE PROPERTIES COMPANY
To: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
Reel/Frame 066436/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2023
From: KCI LICENSING, INC.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 064718/0544 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Nov 7, 2019
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: KCI USA, INC.; KCI LICENSING, INC.
Reel/Frame 050966/0547 →
RELEASE OF SECURITY INTEREST REEL/FRAME 040098/0268 Recorded Feb 8, 2017
From: WILMINGTON TRUST
To: KCI USA, INC.
Reel/Frame 041666/0320 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2012
From: HANSON, DOUGLAS PHILIP
To: KCI LICENSING, INC.
Reel/Frame 029498/0268 →
Cited By (1)
US 12,697,374